Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abituzumab + Cetuximab + FOLFIRI in Metastatic Colorectal Cancer
NCT03688230Phase 2Withdrawn
- Sponsor
- SFJ Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Abituzumab + Cetuximab + FOLFIRI with Placebo + Cetuximab + FOLFIRI (2 arms). Primary endpoint: Progression Free Survival at 16 months. Planned start Apr 2019; status: withdrawn.
02
Drugs
abituzumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03688230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03688230.